MEP of the week
Vytenis Povilas Andriukaitis, official European Parliament portrait

Member of the European Parliament · Lithuania S&D

Vytenis Povilas Andriukaitis

MEP for Lithuania · Socialists & Democrats · Lietuvos socialdemokratų partija · official EP profile

As of 8 November 2026, Vytenis Povilas Andriukaitis (S&D, Lithuania) has declared 213 lobby meetings this term - rank 96 of 720 MEPs by declared meetings, a place shared with 2 other MEPs.

That is one of the fuller declaration sheets in the Parliament - 2.1× the average member, and it ranks 24 of 135 in the S&D group.

68% of this MEP's declared counterpart entries, including diplomatic and government entries, carry a declared EU Transparency Register link - above the like-for-like raw Parliament-wide share of 52%.

213
declared meetings
current term
213
records since 2016
full dataset
68%
all counterpart entries linked
incl. diplomacy; vs 52% EP‑wide
96/720
rank, all MEPs
tied with 2 others
24/135
rank in S&D

Compare with the rest: search and sort all 720 MEPs, or see every MEP from Lithuania.

Compared with the averages

Vytenis Povilas Andriukaitis, this term
213
Parliament average
100
S&D average
134

Transparency this term

Monthly declared meetings (bars) and the share of all counterpart entries carrying a declared Register link, including diplomatic and government entries (line), July 2024 to November 2026. This is the same current-term window as the figures above, beginning 16 July 2024.

Current month, partial through 6 Nov 2026: 0 declared meetings in Nov 2026. Peak: 15 in Jan 2025.

0%25%50%75%100%015July 2024: 9 declared meetingsAugust 2024: 1 declared meetingSeptember 2024: 12 declared meetingsOctober 2024: 12 declared meetingsNovember 2024: 10 declared meetingsDecember 2024: 11 declared meetingsJanuary 2025: 15 declared meetingsFebruary 2025: 12 declared meetingsMarch 2025: 14 declared meetingsApril 2025: 8 declared meetingsMay 2025: 7 declared meetingsJune 2025: 7 declared meetingsJuly 2025: 8 declared meetingsAugust 2025: 0 declared meetingsSeptember 2025: 8 declared meetingsOctober 2025: 4 declared meetingsNovember 2025: 8 declared meetingsDecember 2025: 4 declared meetingsJanuary 2026: 4 declared meetingsFebruary 2026: 5 declared meetingsMarch 2026: 14 declared meetingsApril 2026: 12 declared meetingsMay 2026: 10 declared meetingsJune 2026: 7 declared meetingsJuly 2026: 3 declared meetingsAugust 2026: 0 declared meetingsSeptember 2026: 4 declared meetingsOctober 2026: 4 declared meetingsNovember 2026: 0 declared meetingsnew termMonths with no declared meetings have no Register-share value; the dashes join the months either sideMonthly share of all counterpart entries carrying a declared Register link2024202520260%25%50%75%100%015July 2024: 9 declared meetingsAugust 2024: 1 declared meetingSeptember 2024: 12 declared meetingsOctober 2024: 12 declared meetingsNovember 2024: 10 declared meetingsDecember 2024: 11 declared meetingsJanuary 2025: 15 declared meetingsFebruary 2025: 12 declared meetingsMarch 2025: 14 declared meetingsApril 2025: 8 declared meetingsMay 2025: 7 declared meetingsJune 2025: 7 declared meetingsJuly 2025: 8 declared meetingsAugust 2025: 0 declared meetingsSeptember 2025: 8 declared meetingsOctober 2025: 4 declared meetingsNovember 2025: 8 declared meetingsDecember 2025: 4 declared meetingsJanuary 2026: 4 declared meetingsFebruary 2026: 5 declared meetingsMarch 2026: 14 declared meetingsApril 2026: 12 declared meetingsMay 2026: 10 declared meetingsJune 2026: 7 declared meetingsJuly 2026: 3 declared meetingsAugust 2026: 0 declared meetingsSeptember 2026: 4 declared meetingsOctober 2026: 4 declared meetingsNovember 2026: 0 declared meetingsnew termMonths with no declared meetings have no Register-share value; the dashes join the months either sideMonthly share of all counterpart entries carrying a declared Register link2024202520260%50%100%015202420252026
declared meetings per month (left axis)all counterpart entries carrying a declared Register link; diplomacy included (right axis)
Show the figures for each monthHide the monthly figures
Declared meetings each month, and the share of all counterpart entries carrying a declared Register link.
MonthMeetingsLinked
Jul 2024940%
Aug 20241100%
Sep 20241250%
Oct 20241277.8%
Nov 20241090%
Dec 20241191.7%
Jan 20251582.4%
Feb 20251284.6%
Mar 20251471.4%
Apr 2025862.5%
May 2025787.5%
Jun 2025785.7%
Jul 2025850%
Aug 20250-
Sep 2025850%
Oct 2025450%
Nov 2025850%
Dec 202540%
Jan 2026475%
Feb 2026540%
Mar 20261466.7%
Apr 20261278.9%
May 20261046.2%
Jun 2026757.1%
Jul 2026366.7%
Aug 20260-
Sep 2026450%
Oct 2026480%
Nov 20260-

Busiest month: 15 declared in January 2025. Months with no declared meetings have no Register-share value; a dashed stretch of the line joins the months either side.

Who Vytenis Povilas Andriukaitis meets most

Counterparts are merged by resolved Transparency Register identity where possible. An entry counts as register-linked above only when the MEP declaration itself carries a Register link.

Where the meetings cluster

Both lists count this term. Sector pages count the full 2016–2026 record, and committee pages show each member's current-term total across all subjects, so their figures for this member can be higher.

Most-met sectors this term

Health & pharma (117), Think tanks & research (20), Public affairs & consultancy (13)

Meetings by committee or delegation this term

Public Health (50), Environment, Climate and Food Safety (3), Delegation for relations with Central Asia (1), Delegation to the EU-Armenia, EU-Azerbaijan and EU-Georgia parliamentary committees (1)

Most recent declared meetings

DateCounterpartCapacitySubject
15 Oct 2026Rud Pedersen Brussels⁠↗; IQVIA Solutions B.V.⁠↗RapporteurBiotech
12 Oct 2026A. Menarini Industrie Farmaceutiche Riunite s.r.l.⁠↗RapporteurBiotech Act
7 Oct 2026Eastern and Central European and Central Asian Commission on Drug Policy⁠↗MemberDrug Policy Reform
6 Oct 2026Permanent Representation of the Czech Republic to the European Union Permanent Representation of the Slovak Republic to the European UnionRapporteurBiotech Act
30 Sep 2026Health Policy WatchMemberExchange of views
15 Sep 2026Mission of the United Kingdom to the EURapporteurBiotech Act
8 Sep 2026Friends of Europe⁠↗MemberEuropean Biotechnology sector
1 Sep 2026European Society of Anaesthesiology and Intensive Care⁠↗MemberExchange of views
14 Jul 2026EURORDISMemberRare Diseases
8 Jul 2026Kangaroo Group⁠↗MemberHealth as geopolitical asset
Show 20 more meetingsShow fewer meetings
DateCounterpartCapacitySubject
6 Jul 2026EuropaBio⁠↗MemberEuropean Biotech Sector
30 Jun 2026Mission of Republic Moldova to the EUMemberEnlargement
24 Jun 2026BEAM Alliance⁠↗MemberExchange of Views
23 Jun 2026Genmab A/S⁠↗RapporteurBiotech Act
22 Jun 2026European Landowners’ OrganizationMemberFuture of Ukraine's agricultural acession
17 Jun 2026Permanent Representation of the Kingdom of the Netherlands to the European UnionRapporteurBiotech Act
17 Jun 2026CropLife Europe⁠↗RapporteurBiotech Act and Food and Feed Omnibus
2 Jun 2026Merck⁠↗RapporteurBiotech Act
21 May 2026A. Menarini Industrie Farmaceutiche Riunite s.r.l.RapporteurBiotech Act
21 May 2026Copa-CogecaMemberNGT
20 May 2026Kangaroo Group⁠↗MemberEU Own Resources discussion
18 May 2026EUROPEAN ORGANISATION FOR RARE DISEASES⁠↗RapporteurBiotech Act
13 May 2026BIOTON S.A.; Bayer AG⁠↗; Deutsche Sozial­versicherung Europa­vertretung European Federation of Pharmaceutical Industries and Associations IQVIA Solutions B.V. MEDICINES FOR EUROPE Rijks­instituut voor ziekte- en invaliditeits­verzekeringRapporteurBiotech Act
12 May 2026European Centre for Disease Prevention and Control (ECDC); IQVIA Solutions B.V.⁠↗RapporteurBiotech Act
8 May 2026The Brewers of Europe⁠↗MemberFood labeling
7 May 2026European CRO Federation European Federation of Pharmaceutical Industries and Associations IQVIA Solutions B.V.RapporteurBiotech Act
4 May 2026EFPIARapporteurBiotech act
4 May 2026GSK⁠↗RapporteurBiotech Act
28 Apr 2026American Chamber of Commerce to the European Union⁠↗; Brunswick Group Limited srl⁠↗; EUCOPERapporteurBiotech Act
22 Apr 2026Kaneka Belgium N.V.⁠↗; Food Supplements Europe⁠↗; Bristol-Myers Squibb Company⁠↗RapporteurBiotech act

The full record is in the official EP declarations.

Roll-call voting record

Recorded votes only. Parliament held 6,412 roll-call votes while Vytenis Povilas Andriukaitis held the seat, 606 of them the final vote on a text. A member with no vote recorded may have been on parliamentary business, ill, on leave, or present without voting - the published record does not distinguish these and gives no reason. Votes taken by show of hands or by secret ballot are not recorded by name and are absent here.

96%
roll-calls with a vote recorded
of 6,412 held while seated
591
final texts voted on
of 606
93%
voted with the S&D majority
on 589 final texts
41
differed from S&D
listed below

How they voted on final texts

Share of the 606 final votes held while seated.

Vytenis Povilas Andriukaitis606 final votes
82%10%
For 497Against 58Abstained 36No vote recorded 15

With and against the group

On the 589 final texts where more than half of S&D members casting a vote went one way, and Vytenis Povilas Andriukaitis also voted. Groups are not bound to vote together: a Member's mandate is personal and exercised freely, so neither figure is a measure of performance.

Voted with the S&D majority54893%
Voted differently417%

Final texts where Vytenis Povilas Andriukaitis differed from the S&D majority

DateTextTheir voteS&D majority
21 October 2026Motion for a resolution on the draft Commission implementing decision renewing the authorisation for placing on the market of products containing, consisting of or produced from genetically modified soybean MON 87769 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council B10-0469/2026 · Motion for a resolution (as a whole)AbstainedFor
16 September 2026Motion for a resolution on the draft Commission implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified soybean MON 94313 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council B10-0379/2026 · Motion for a resolutionAbstainedFor
16 September 2026Motion for a resolution on the draft Commission implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified soybean GMB151 x DAS-44406-6 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council B10-0380/2026 · Motion for a resolutionAbstainedFor
16 September 2026Motion for a resolution on the draft Commission implementing decision renewing the authorisation for the placing on the market of products containing, consisting of or produced from genetically modified maize MON 87460 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council B10-0381/2026 · Motion for a resolutionAbstainedFor
15 September 2026Amending Decision (EU) 2015/1814 as regards ceasing the invalidation of allowances in the market stability reserve A10-0230/2026 · Pierfrancesco Maran · Commission proposalAgainstFor
8 July 2026Motion for a resolution on the Commission Implementing Decision renewing the authorisation for the placing on the market of products containing, consisting of or produced from genetically modified maize NK603 × T25 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council B10-0335/2026 · Motion for a resolution (as a whole)AbstainedFor
8 July 2026Motion for a resolution on the draft Commission Implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified maize DP202216 x NK603 x DAS-40278-9 and its sub-combinations DP202216 x NK603, DP202216 x DAS-40278-9, pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council B10-0336/2026 · Motion for a resolution (as a whole)AbstainedFor
8 July 2026Motion for a resolution on the draft Commission implementing decision renewing the authorisation for the placing on the market of products containing, consisting of or produced from genetically modified soybean MON 87705 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council B10-0334/2026 · Motion for a resolution (as a whole)AbstainedFor
21 May 2026Advancing towards a care society: addressing the gender care gap A10-0083/2026 · Eleonora Meleti and Rosa Estaràs Ferragut · Motion for a resolution (as a whole)AgainstAbstained
30 April 2026RC-B10-0217/2026 - Joint motion for a resolution (subject not given in the vote record) RC-B10-0217/2026 · Motion for a resolution (as a whole)AbstainedFor

31 further instances are not listed. All roll-call votes.

Unlinked but matchable

42 counterpart entries in Vytenis Povilas Andriukaitis's declarations appear to match an EU Transparency Register entry without being linked in the declaration:

These are the 3 most frequent matches, covering 11 of the 42 entries; the other 31 are not listed.

Matching is automated and can be wrong - see how matching works. Linking the register entry is the fix, and it is the MEP office's to make.